FDA Law Blog: Biosimilars

JUNE 10, 2024

Walsh — Among FDA-regulated establishments and stakeholders, there is one word that makes everyone go on edge – the dreaded FDA “inspection.” In FY2023, FDA conducted over 1000 inspections under the BIMO program. We also detail some of our recommended best practices to achieve success when FDA comes knocking.

FDA 111

FDA Compliance Laboratories International 111

BioPharma Drive: Drug Pricing

APRIL 1, 2025

A Texas judge vacated the FDA’s final rule, which was strongly opposed by the laboratory industry, and remanded the matter to HHS Secretary Robert F. Kennedy Jr.

Regulations 130

Regulations Laboratories FDA 130

Agency IQ

JUNE 16, 2023

FDA set to unveil new rule on Laboratory Developed Tests this August Following challenges getting a diagnostics reform package through Congress, known as the VALID Act, the FDA has just announced that it plans to release a proposed rule in August 2023 that would change the way that the agency effectively regulates laboratory developed tests (LDTs).

Laboratories 52

Laboratories FDA Packaging Regulations 52

Collaborative Drug

OCTOBER 7, 2024

CDD Vault provides conventional SAR tables of course, but it also gives you access to data from multiple public sources for comparison with hundreds of published sources, including popular MLSMR, GlaxoSmithKline TCAMs, and FDA-Approved Re-purposed Drugs data sets.

FDA Approval 264

FDA Approval Laboratories FDA Research 264

Drug Target Review

JULY 7, 2025

But growing ethical scrutiny, supply shortages, cost burdens, scientific innovation and regulatory shifts like the US Food and Drug Administration (FDA)’s new alternative methods roadmap are bringing the continued reliance on live NHPs into question, and opening the door to next-generation solutions that could eventually replace them altogether.

Drug Research 52

Drug Research Research Animal Testing Drugs 52

FDA Law Blog: Biosimilars

SEPTEMBER 22, 2024

The webinar largely consisted of summarizing the general requirements under Parts 803, 806 and 820.198, which we do not reproduce here ( but see another of our prior blog posts discussing these requirements and their applicable to LDTs in greater detail; you can also find FDA’s slides from the webinar here ).

FDA 64

FDA Laboratories Regulations Compliance 64

FDA Law Blog: Biosimilars

APRIL 14, 2025

Baumhardt, Principal Medical Device Regulatory Expert In January 2025, FDA posted the 2024 Annual Report concerning the Accreditation Scheme for Conformity Assessment (ASCA) program as required by Medical Device User Fee Amendments of 2017 (MDUFA IV).

Laboratories 59

Laboratories FDA International 59

The Pharma Data

JUNE 9, 2025

FDA Approves Merck’s ENFLONSIA™ to Protect Infants from Severe RSV Illness Merck operating as MSD outside the United States and Canada, has received a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting approval for ENFLONSIA™ (clesrovimab-cfor). A New Era in Infant RSV Protection Dr. Dean Y.

FDA Approval 40

FDA Approval FDA Hospitals Clinical Trials 40

FDA Law Blog: Biosimilars

DECEMBER 11, 2023

Mullen — With comments due on the proposed LDT rule last week, FDA wasted no time updating the Unified Agenda to indicate that a final rule may be published in April ( here ). Under the Administrative Procedure Act, FDA is obligated to address major substantive issues when – and not so much if – it publishes a final rule.

FDA 69

FDA Laboratories Regulations Production 69

FDA Law Blog: Biosimilars

MARCH 25, 2025

Lenz, Principal Medical Device Regulation Expert Last year, FDA issued a letter to the medical device industry warning medical device firms of concerns related to fraudulent and unreliable laboratory testing data in premarket submissions, which we blogged about here. By Adrienne R.

Laboratories 59

Laboratories FDA Regulations 59

thought leadership

SEPTEMBER 26, 2024

On May 6, 2024, the US Food and Drug Administration (FDA) issued the Final Rule regarding regulation of laboratory developed tests (LDTs). The LDT Final Rule outlines a four-year phaseout period for the enforcement discretion approach that FDA has previously exercised for LDTs.

FDA 58

FDA Laboratories Regulations Drugs 58

FDA Law Blog: Biosimilars

FEBRUARY 4, 2024

Mullen — On January 18, 2024, the director of FDA’s Center for Devices and Radiological Health and the chief medical officer and acting director of CMS’ Center for Clinical Standards and Quality issued a joint press release supporting FDA’s recent proposed rule regulating Laboratory Developed Tests (LDTs).

FDA 59

FDA Laboratories Regulations Compliance 59

FDA Law Blog: Biosimilars

MARCH 31, 2024

Gibbs — On March 21, 2024, the House Energy and Commerce held a subcommittee hearing titled “Evaluating Approaches to Diagnostic Test Regulation and the Impact of the FDA’s Proposed Rule.” They believe any regulatory oversight for laboratory developed tests (LDTs) should be mandated by Congress, rather than the Executive Branch.

Regulations 64

Regulations FDA Laboratories Hospitals 64

Conversations in Drug Development Trends

JANUARY 21, 2025

Jayaprakash Kotha, MBBS, PhD, ASCP (SH), Vice President, Bioanalytical Laboratory Satish Kumar, MBB, Head of Process Improvement Continuous Innovation is a Cornerstone of Bioanalysis Approximately 80% of drugs that begin the research process fail to reach approval. What is one contributing factor that sets the 20% that do apart from the rest?

Clinical Trials 78

Clinical Trials Laboratories Trials Drug Development 78

FDA Law Blog: Biosimilars

JULY 10, 2023

After a firm submits a 510(k) to FDA, FDA will request still more information after a first-pass review. According to the 2 nd Quarter FY2023 MDUFA V Performance Report , FDA issued a request for additional information (AI request) on the first FDA review cycle for 63% to 68% of 510(k)s submitted in FY2018 to FY2022.

FDA 75

FDA Packaging Laboratories Engineering 75

FDA Law Blog: Biosimilars

NOVEMBER 1, 2023

Gibbs — For more than three decades, FDA has claimed that the Federal Food, Drug & Cosmetic (FD&C Act) gives the agency legal authority to regulate laboratory developed tests (LDTs) as medical devices (see our prior post here ). Lenz, Principal Medical Device Regulation Expert & Sophia R. Gaulkin & Jeffrey N.

Laboratories 81

Laboratories FDA Regulations Licensing 81

FDA Law Blog: Biosimilars

MAY 27, 2024

On the premarket side, in addition to the preparation of pre-submission and submission materials for FDA, Jennifer assists clients in responding to inquiries from FDA during the review process and participating in meetings with clients to address FDA concerns. Ellison, Managing Director at HPM.

Laboratories 59

Laboratories Compliance FDA Regulations 59

Quanticate

JUNE 13, 2025

Clinical research generates vast amounts of diverse data from laboratory tests, patients, medical equipment, and outside sources. By organising and analysing this information, researchers can extract actionable insights that improve patient outcomes, data accuracy, drug efficacy and speed up trials.

Clinical Trials 52

Clinical Trials Trials Laboratories Clinical Research 52

thought leadership

NOVEMBER 14, 2023

Food and Drug Administration (FDA) issued a proposed rule to amend its enforcement approach to Laboratory Developed tests (LDTs). On October 3rd, 2023, the U.S.

Regulations 59

Regulations FDA Laboratories Production 59

ProRelix Research

DECEMBER 15, 2021

­­Drug development strategy for US FDA It takes a staggering 12 years on an average for a drug to travel from the laboratory bench to your bedside! The post Drug development strategy for US FDA appeared first on ProRelix Research. This is coupled […].

Drug Development 52

Drug Development FDA Laboratories Drugs 52

Agency IQ

JULY 22, 2024

BY LAURA DIANGELO, MPH In April 2024, the FDA issued a final rule to update its regulatory approach to certain test products known as Laboratory Developed Tests (LDTs).

FDA 59

FDA Laboratories Regulations Drug Development 59

Agency IQ

MAY 28, 2024

BY RACHEL COE, MSC The House E&C Health Subcommittee Hearing on May 22 featured an extensive grilling of the leaders of FDA’s three medical products centers: CDER, CBER and CDRH. Fill out the form to read the full article.

Production 59

Production FDA Laboratories 59

FDA Law Blog: Biosimilars

MAY 15, 2024

On April 29, the FDA issued their long-awaited, controversial Final Rule governing the oversight of laboratory developed tests ( LDTs ). This new rule will dramatically alter the LDT regulatory landscape, while at the same time requiring significant operational changes and posing strategic challenges for many LDTs.

Laboratories 59

Laboratories Government FDA 59

Common Sense for Drug Policy Blog

OCTOBER 29, 2024

Limited Evidence for Nalfmefene "In 2021, due to the widespread availability of high-potency synthetic opioids like fentanyl, the US FDA approved two high-dose naloxone products, an 8 mg IN spray (Kloxxado) and a 5 mg IM injectable (Zimhi). In 2023, the FDA approved a 2.7 mg IM vs. 8 mg IN and 2 mg IM vs. 5 mg IM, respectively).

FDA Approval 52

FDA Approval Pharmacokinetics Packaging FDA 52

Advarra

JUNE 26, 2023

Food and Drug Administration (FDA) guidelines is critical to the success, failure, or delay of delivering life-changing therapies to market. A successful FDA inspection can pave the way for continued operations, product approvals, and in some cases, even accelerated go-to-market regulatory pathways.

FDA 52

FDA Compliance Regulations International 52

Broad Institute

JULY 17, 2024

Predictive models don’t eliminate laboratory experiments, but they can help researchers narrow the selection pool of potential drugs, allocating more time and resources to experiment on the more promising candidates. Since the FDA released these datasets, we wondered if we could use them to predict toxicity using machine learning," said Seal.

Pharmacokinetics 124

Pharmacokinetics Molecular Biology Drugs FDA 124

Agency IQ

MAY 3, 2024

The FDA recently issued a new rule to overhaul its enforcement policies for laboratory developed tests (LDTs), and has also issued two accompanying guidance documents outlining implications and new expectations for emergency response and what an emergency-related enforcement discretion would potentially look like going forward.

FDA 59

FDA Laboratories Regulations 59

FDA Law Blog: Biosimilars

OCTOBER 6, 2023

Javitt & Philip Won — As we reported last week, FDA has issued a 26 page, single spaced, tiny-font Proposed Rule of Laboratory Developed Tests (LDTs). The brevity of this change belies the foreseeably seismic impact of FDA regulation of clinical laboratories on the healthcare system. By Allyson B. Mullen & Gail H.

Laboratories 64

Laboratories FDA Regulations Production 64

Conversations in Drug Development Trends

NOVEMBER 27, 2023

Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow. In June 2023, the U.S.

Treatment 75

Treatment FDA Clinical Trials Therapies 75

The Pharma Data

JUNE 2, 2023

Food and Drug Administration (FDA) for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. In the U.S., For the U.S.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

Agency IQ

JULY 22, 2024

Facing headwinds, FDA moves ahead on diagnostics policy implementation but faces Congressional, legal, and judicial questions In April 2024, the FDA issued a final rule to update its regulatory approach to certain test products known as Laboratory Developed Tests (LDTs). diagnostic products are regulated as medical devices.

FDA 40

FDA Laboratories Regulations Clinical Trials 40

Agency IQ

DECEMBER 15, 2023

Key stakeholders weigh in on FDA’s Laboratory Developed Test Rule. The 60-day comment period on the FDA’s proposed rule to revamp the way that laboratory developed tests (LDTs) are regulated ended on December 4th, 2023. While the FDA has traditionally regulated diagnostic products as medical devices in the U.S.,

Laboratories 40

Laboratories Science FDA Regulations 40

FDA Law Blog: Biosimilars

DECEMBER 6, 2023

filed comments on behalf of the Coalition to Preserve LDT Access and Innovation in response to FDA’s proposed rule to regulate laboratory developed tests (LDTs) as devices. As a threshold matter, FDA lacks the power to regulate tests developed and used in a laboratory.

Laboratories 59

Laboratories FDA Regulations Compliance 59

FDA Law Blog: Drug Discovery

JANUARY 12, 2025

Sasinowski On December 5, 2024, FDA published a new draft guidance on accelerated approval providing a much needed and substantial update to its guidance on the pathway. FDAs application and use of accelerated approval has evolved dramatically since it was first developed by the Agency to help address the HIV/AIDS epidemic in the late 1980s.

FDA 64

FDA Clinical Trials Trials Therapies 64

FDA Law Blog: Biosimilars

FEBRUARY 6, 2024

PM Counsel John Claud to testify yesterday about FDA’s foreign inspection program. We’ve blogged previously on the troubles FDA has faced ramping up its foreign inspections program after the pandemic. Thakur is a public health advocate and a former executive at Ranbaxy Laboratories in India.

Testimonials 52

Testimonials FDA International Laboratories 52

FDA Law Blog: Biosimilars

SEPTEMBER 29, 2023

Today, FDA released a copy of a proposed rule to regulate laboratory-developed tests (LDTs), which is scheduled to be published in the Federal Register on October 3rd. For more than 30 years, FDA has asserted that it has jurisdiction to regulate LDTs as medical devices and clinical laboratories as manufacturers.

Laboratories 59

Laboratories Regulations FDA Disease 59

Agency IQ

JUNE 26, 2023

While the pilot has been in development for a while, the move comes as the FDA is looking towards a broader shift in its approach to LDTs.

FDA 52

FDA Science Laboratories Drugs 52